|
Response Rate to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer Based on Common Molecular Receptors
|
Abdolreza Fazel1    , Seyed Reza Khandoozi * 2, Gholamreza Roshandel3 , Farzad Bagherian4 |
1- Associate Professor of Surgery, Cancer Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
2- Assistant Professor, Cancer Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. , drkhandoozi92002@yahoo.com
3- Associate Professor of Epidemiology, Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences, Gorgan, Iran.
4- General Surgery Specialist, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. |
|
|
Abstract: (1486 Views) |
Background and Objective: Breast cancer has a high prevalence and mortality rate in the world and also in Iran. Neoadjuvant chemotherapy (NAC) is one of the treatment methods to improve patient survival. This study aimed to determine the response rate to NAC in patients with locally advanced breast cancer based on common molecular receptors.
Methods: This descriptive-analytical study was conducted on 100 patients with breast cancer (mean age= 41.14±10.06 years) referring to the surgical clinic of the Fifth Azar Educational and Therapeutic Center in Gorgan, Iran during 2013-18. Patients without distant metastasis underwent NAC treatment regimen followed by surgery. Demographic characteristics, types of drugs, and molecular receptor characteristics, and their response to treatment were recorded in a checklist. Treatment response and overall patient survival were evaluated.
Results: The mean tumor size before NAC was 3.01±2.47 cm (range= 0-8, median= 2) and 16% were determined to be grade one, 52% were determined to be grade 2, and 32% were determined to be grade 3. Thirty-six percent of patients had a positive family history. Forty-six percent were estrogen receptor (ER) positive, 40% were PR positive, 22% were human epidermal growth factor receptor 2 (Her-2) positive, and 78% were Her-2 negative. Thirty-six percent had a Ki-67 index greater than 30%. Eighteen percent of patients had a complete pathological response, and 82% had a partial or negative response. In terms of family history of breast cancer, Her2, ER, progestrone receptor (PR), Ki-67 receptor status, histological grade, tumor size, and axillary lymph nodes, there was a significant statistical difference between the two groups with and without complete pathological response (P<0.05).
Conclusion: The rate of complete pathological response to NAC in patients with locally advanced breast cancer was 18%. |
|
Keywords: Breast Neoplasms [MeSH], Chemotherapy Adjuvant [MeSH], Pathologic Complete Response [MeSH], Survival [MeSH], Mortality [MeSH]
Article ID: Vol26-27 |
|
|
Full-Text [PDF 610 kb]
(3506 Downloads)
| | Abstract (HTML) (93 Views)
|
|
Type of Study: Original Articles |
Subject:
Oncology
|
|
|
|
|
|
|
| References |
1. Naderimagham S, Alipour S, Djalalinia S, Kasaeian A, Noori A, Rahimzadeh S, et al. National and sub-national burden of breast cancer in Iran; 1990-2013. Arch Iran Med. 2014 Dec;17(12):794-99. [ PubMed] 2. López-Abente G, Mispireta S, Pollán M. Breast and prostate cancer: an analysis of common epidemiological features in mortality trends in Spain. BMC Cancer. 2014 Nov;14:874. doi: 10.1186/1471-2407-14-874. [ DOI] [ PubMed] 3. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 Mar;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. [ DOI] [ PubMed] 4. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007 Jul-Aug;13(4):383-91. doi: 10.1111/j.1524-4741.2007.00446.x. [ DOI] [ PubMed] 5. Guaoua S, Ratbi I, Lyahyai J, El Alaoui SC, Laarabi FZ, Sefiani A. Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer. Afr Health Sci. 2014 Jun;14(2):468-71. doi: 10.4314/ahs.v14i2.25. [ DOI] [ PubMed] 6. Sapkota Y. Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res. 2014;144(2):77-91. doi: 10.1159/000369045. [ DOI] [ PubMed] 7. Elkum N, Al-Tweigeri T, Ajarim D, Al-Zahrani A, Amer SM, Aboussekhra A. Obesity is a significant risk factor for breast cancer in Arab women. BMC Cancer. 2014 Oct;14:788. doi: 10.1186/1471-2407-14-788. [ DOI] [ PubMed] 8. Thompson CL, Owusu C, Nock NL, Li L, Berger NA. Race, age, and obesity disparities in adult physical activity levels in breast cancer patients and controls. Front Public Health. 2014 Sep;2:150. doi: 10.3389/fpubh.2014.00150. [ DOI] [ PubMed] 9. DeVita VTJr, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology (Cancer: Principles & Practice (DeVita). 9th ed. Philadelphia: Lippincott Williams & Wilkins. 2011; pp: 1401-46. 10. Alvarado-Cabrero I, Alderete-Vázquez G, Quintal-Ramírez M, Patiño M, Ruíz E. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol. 2009 Jun;13(3):151-57. doi: 10.1016/j.anndiagpath.2009.02.003. [ DOI] [ PubMed] 11. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct;23(28):7098-104. doi: 10.1200/JCO.2005.11.124. [ DOI] [ PubMed] 12. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005 Jan;92(1):14-23. doi: 10.1002/bjs.4840. [ DOI] [ PubMed] 13. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb;97(3):188-94. doi: 10.1093/jnci/dji021. [ DOI] [ PubMed] 14. Andrade DA, Zucca-Matthes G, Vieira RA, Andrade CT, Costa AM, Monteiro AJ, et al. Neoadjuvant chemotherapy and pathologic response: a retrospective cohort. Einstein (Sao Paulo). 2013 Dec;11(4):446-50. doi: 10.1590/s1679-45082013000400007. [ DOI] [ PubMed] 15. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007 Jul;25(19):2650-55. doi: 10.1200/JCO.2006.08.2271. [ DOI] [ PubMed] 16. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006 Apr;24(12):1940-49. doi: 10.1200/JCO.2005.02.6187. [ DOI] [ PubMed] 17. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. [ DOI] [ PubMed] 18. Zhang W, Tian H, Yang SH. The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis. Anal Cell Pathol (Amst). 2017;2017:1350618. doi: 10.1155/2017/1350618. [ DOI] [ PubMed] 19. Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014 Oct;21(10):3317-23. doi: 10.1245/s10434-014-3922-0. [ DOI] [ PubMed] 20. Morrow M. Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. JAMA Oncol. 2016 Apr;2(4):516-17. doi: 10.1001/jamaoncol.2015.4919. [ DOI] [ PubMed] 21. Erbes T, Orlowska-Volk M, Zur Hausen A, Rücker G, Mayer S, Voigt M, et al. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer. 2014 Jan;14:4. doi: 10.1186/1471-2407-14-4. [ DOI] [ PubMed] 22. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer. 2010 Mar;116(5):1243-51. doi: 10.1002/cncr.24887. [ DOI] [ PubMed] 23. Tafazzoli Harandi H, Olfatbakhsh A, Najjar Najafi S, Hosseinpour P, Mokhtari Hesari P, Hashemi EA. [Complete Pathologic Response after neo-adjuvant Chemotherapy in Breast Cancer and Its Effective Factors: A Single-center Study]. IJBD. 2015;8(1):7-14. [Article in Persian] [ Link] |
|
| Send email to the article author |
|
|
|
Fazel A, Khandoozi S R, Roshandel G, Bagherian F. Response Rate to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer Based on Common Molecular Receptors. J Gorgan Univ Med Sci 2024; 26 (3) :53-59 URL: http://goums.ac.ir/journal/article-1-4386-en.html
|
